![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eirx Therap. | LSE:ERX | London | Ordinary Share | GB00B0XQBS97 | ORD 0.001P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.015 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:9957P EiRx Therapeutics PLC 13 March 2008 EIRX THERAPEUTICS PLC ( "EiRx" or "the Company" ) Restoration of trading on AIM and Business update The Directors of EiRx Therapeutics plc are pleased to note the restoration of the Company's shares to trading on AIM. The Company can confirm that the suspension affected neither the Company's business nor the fundraising announced on 19 February 2008. Business Update As part of the Company's ongoing efforts to streamline its organisation and focus expenditure on critical activities necessary for value enhancement, EiRx is this month closing its Aberdeen facility and relocating the operations of its Auvation subsidiary to Cork. These activities include the cancer biomarker effort undertaken in collaboration with bioMerieux SA, and revenue generation from licensing of laboratory research reagents. The ACCRI-BANK tissue specimen collection remains housed within the Pathology Department at the University of Aberdeen Medical School, and the conditions of the Company's access to this resource are unchanged. Interim results The Company will announce its results for the six months ended 31 December 2007 on 28 March 2008. Commenting on recent events, EiRx CEO Colin Telfer said: " With the benefit of the fundraising announced in February, we look forward to advancing the Company's lead product programmes into medicinal chemistry via our collaboration with Professor Anita Maguire and the Analytical and Biological Chemistry Research Facility (ABCRF) at University College Cork. The Company will also continue to drive expansion and deployment of the EnPADTM drug discovery engine as well as seeking licensing and other business development opportunities." For further information, please contact: EiRx Therapeutics plc +353 (0)21 432 0847 Colin Telfer PhD, Chief Executive Officer Grant Thornton Corporate Finance +44 (0)20 7383 5100 Philip Secrett / Colin Aaronson About EiRx EiRx Therapeutics (AIM: ERX) is a research-driven healthcare company developing cutting-edge targeted therapies for the treatment of cancer. Headquartered in Cork, Ireland, the Company conducts drug discovery focused on tumours arising due to anomalies in apoptosis and cellular growth regulatory pathways, with particular relation to breast and colorectal tumours, currently two of the four leading causes of death from cancer world-wide. EiRx is built on leading scientific expertise in the areas of apoptosis biology, cancer pathway biology, biomarker technologies and the metabolic basis of drug resistance in tumours. It has established technical capabilities in target identification, validation and cell-based screening, and is combining unique resources such as the ACCRI-BANK clinical tissue bank, the ALIBITM functional genomics platform and the Engineered Pathway Dependence ("EnPADTM") isogenic cellular screening technology to create a product development engine specialising in discovery and development of small-molecule targeted cancer therapies and the discovery and validation of cancer biomarkers. For further information please see our website at http://www.eirx.com This information is provided by RNS The company news service from the London Stock Exchange END STRILFIAVTIFLIT
1 Year Eirx Therapeutics Chart |
1 Month Eirx Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions